Candocuronium iodide

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Candocuronium iodide" – news · newspapers · books · scholar · JSTOR (June 2014) (Learn how and when to remove this message) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (June 2014) (Learn how and when to remove this message) The topic of this article may not meet Wikipedia's general notability guideline. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "Candocuronium iodide" – news · newspapers · books · scholar · JSTOR (June 2014) (Learn how and when to remove this message) This article contains wording that promotes the subject in a subjective manner without imparting real information. Please remove or replace such wording and instead of making proclamations about a subject's importance, use facts and attribution to demonstrate that importance. (June 2014) (Learn how and when to remove this message) (Learn how and when to remove this message)

Candocuronium iodide

Clinical data
Other names	Chandonium iodide; HS-310
Pregnancy category	Not applicable
Routes of administration	IV
ATC code	none
Legal status
Legal status	Discontinued from clinical development
Pharmacokinetic data
Bioavailability	100% (IV)[citation needed]
Identifiers
IUPAC name (4aS,4bR,8S,10aR,10bS,12aS)-1,1,10a,12a-tetramethyl-8-(1-methylpyrrolidin-1-ium-1-yl)-3,4,4a,4b,5,7,8,9,10,10b,11,12-dodecahydro-2H-naphtho[2,1-f]quinolin-1-ium diiodide
CAS Number	54278-85-2 Y
PubChem CID	71537
ChemSpider	64610 N
UNII	SC80GNP08C
ChEMBL	ChEMBL2106112 N
CompTox Dashboard (EPA)	DTXSID60969306
Chemical and physical data
Formula	C26H46I2N2
Molar mass	640.477 g·mol−1
3D model (JSmol)	Interactive image
SMILES [I-].[I-].C\53=C/C[C@@H]1[C@H](CC[C@]2([C@H]1CCC[N+]2(C)C)C)[C@@]3(C)CC[C@H]([N+]4(C)CCCC4)C/5
InChI InChI=1S/C26H46N2.2HI/c1-25-14-12-21(28(5)17-6-7-18-28)19-20(25)10-11-22-23(25)13-15-26(2)24(22)9-8-16-27(26,3)4;;/h10,21-24H,6-9,11-19H2,1-5H3;2*1H/q+2;;/p-2/t21-,22+,23-,24-,25-,26-;;/m0../s1 N Key:GGAGIPMNQXAXNH-XDMKMBKMSA-L N
NY (what is this?)  (verify)

Candocuronium iodide (INN, formerly chandonium, HS-310)^[1] is an aminosteroid neuromuscular-blocking drug. Its use within anesthesia for endotracheal intubation and for providing skeletal muscle relaxation during surgery or mechanical ventilation was briefly evaluated in clinical studies in India, though further development was discontinued due to attendant cardiovascular effects, primarily tachycardia that was about the same as the clinically established pancuronium bromide.^[2][3][4][5] Candocuronium demonstrated a short duration in the body, but a rapid onset of action. It had little to no ganglion blocking activity, with a greater potency than pancuronium.^[1]